- Home/In The News/Blog/2014/August
27
August2014
category:
503b CompoundingTeva recalls Parkinson’s disease drug because it may be ‘superpotent’
Teva Pharmaceutical Industries ($TEVA), whose manufacturing operation is being significantly pared down, is recalling one lot of its generic Parkinson’s combo drug carbidopa/levodopa because it may have too much active pharmaceutical ingredient. The drugmaker said the Class II recall involved 3,881 bottles of carbidopa/levodopa 25 mg/100 mg. Teva said that stability testing found that the […]
read more27
August2014
category:
503b CompoundingRegulation of compounding pharmacies continues to evolve with house passage of “Drug Quality and Security Act”
In the current environment it seems that few, if any, pieces of legislation are moving through Capitol Hill. However, there is one area that has seen significant activity: the regulation of compounding pharmacies. Specifically, there has been bipartisan support for legislation intended to bolster the Food and Drug Administration’s (FDA) oversight of compounding pharmacies in […]
read more27
August2014
category:
503b CompoundingCompounding Pharmacies Engaging in Profiteering With “Designer Medications”?
Compounding medications are becoming more commonplace, and more expensive. These designer drugs include a baby rash cream that costs $1600 and a compounded pain treatment cream costing $2388 for a 30 days supply. Many pharmacy benefits managers and healthcare plans are saying that the compounding trend has gotten out of hand. “While creams typically contain about […]
read more